Skip to main content

Danaher Completes Beckman Coulter Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher has completed its acquisition of Beckman Coulter following the expiration last night of a subsequent offering period in the tender offer.

As reported by GenomeWeb Daily News earlier this week, Danaher had completed the tender offer last Friday, with about 88.08 percent of all outstanding shares having been tendered. Following the subsequent offering period, a total of 66,168,634 shares of Beckman common stock representing around 92.38 percent of the outstanding shares had been validly tendered and not withdrawn.

Beckman stockholders who did not tender their shares will receive the offer price of $83.50 per share.

The firms inked the $6.8 billion deal in February. Beckman will become part of Danaher's Life Sciences and Diagnostics segment, joining the AB Sciex, Leica, Radiometer, and Molecular Devices businesses. It provides Danaher with one of the world's largest diagnostics players. Beckman reported full-year 2010 clinical diagnostics sales of $3.21 billion, up 15 percent year over year.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.